Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a conviction-buy rating to a buy rating in a report released on Monday morning, The Fly reports.
ALNY has been the topic of a number of other reports. Stifel Nicolaus upgraded shares of Alnylam Pharmaceuticals from a hold rating to a buy rating and raised their price objective for the company from $95.00 to $125.00 in a report on Monday, August 6th. BidaskClub lowered shares of Alnylam Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, August 2nd. Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals to $118.00 and set an equal weight rating on the stock in a report on Monday, May 7th. Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, July 4th. Finally, Chardan Capital restated a buy rating and issued a $180.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, August 3rd. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating and seventeen have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $142.00.
Shares of ALNY opened at $91.83 on Monday. Alnylam Pharmaceuticals has a twelve month low of $70.76 and a twelve month high of $153.99. The firm has a market capitalization of $9.80 billion, a PE ratio of -16.94 and a beta of 2.31. The company has a current ratio of 13.22, a quick ratio of 13.22 and a debt-to-equity ratio of 0.02.
In related news, SVP Laurie Keating sold 1,563 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $105.04, for a total transaction of $164,177.52. Following the sale, the senior vice president now directly owns 16,063 shares in the company, valued at approximately $1,687,257.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John Maraganore sold 50,000 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, July 25th. The stock was sold at an average price of $105.39, for a total transaction of $5,269,500.00. Following the sale, the chief executive officer now owns 201,297 shares in the company, valued at $21,214,690.83. The disclosure for this sale can be found here. 3.70% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the business. Robeco Institutional Asset Management B.V. purchased a new position in Alnylam Pharmaceuticals during the 1st quarter worth $170,000. Mutual of America Capital Management LLC grew its position in Alnylam Pharmaceuticals by 98.5% during the 2nd quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock worth $191,000 after purchasing an additional 960 shares during the last quarter. IPG Investment Advisors LLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $217,000. First Republic Investment Management Inc. purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $230,000. Finally, Riverhead Capital Management LLC grew its position in Alnylam Pharmaceuticals by 195.6% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 1,565 shares during the last quarter. 91.30% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.